Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Dermatology | Family Medicine | Internal Medicine | Pharmacy | Journal

Back to Journal Articles

Lower MI Risk With TNF Inhibitor Therapy for Psoriasis

Last Updated: August 22, 2012.

 

Compared to topical agents, TNF inhibitor treatment tied to lower risk, incidence of heart attack

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Patients with psoriasis who are treated with tumor necrosis factor inhibitors have a significantly lower risk and incidence of myocardial infarction compared with those who are treated with topical agents, according to a study published online Aug. 20 in the Archives of Dermatology.

WEDNESDAY, Aug. 22 (HealthDay News) -- Patients with psoriasis who are treated with tumor necrosis factor (TNF) inhibitors have a significantly lower risk and incidence of myocardial infarction (MI) compared with those who are treated with topical agents, according to a study published online Aug. 20 in the Archives of Dermatology.

Jashin J. Wu, M.D., of the Kaiser Permanente Los Angeles Medical Center, and colleagues conducted a retrospective cohort study involving 8,845 patients to examine the risk of MI associated with TNF inhibitor treatment. The participants included a TNF cohort of 1,673 patients treated with a TNF inhibitor for at least two months; an oral/phototherapy cohort of 2,097 TNF inhibitor-naive patients who received phototherapy or other systemic agents; and a topical cohort of 5,075 who were not treated with TNF inhibitors, systemic therapies, or phototherapy.

After a median follow-up of 4.3 years, and with a medium duration of TNF inhibitor therapy of 685 days, the researchers found that the TNF inhibitor cohort displayed a significantly lower risk of MI compared with those who were treated with topical agents, after adjustment for MI risk factors (adjusted hazard ratio, 0.50). The overall incidence of MI was 3.05, 3.85, and 6.73 per 1,000 patient-years in the TNF inhibitor, oral/phototherapy, and topical cohorts, respectively.

"Use of TNF inhibitors for psoriasis was associated with a significant reduction in MI risk and incident rate compared with treatment with topical agents," the authors write. "Use of TNF inhibitors for psoriasis was associated with a non-statistically significant lower MI incident rate compared with treatment with oral agents/phototherapy."

One author disclosed financial ties to pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Fewer Circumcisions May Increase Infections and Costs Next: Low Back Pain Outcomes Not Improved by Early Imaging

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.